Claims

1. An isolated antibody that binds Interleukin 13 (IL-13), wherein the antibody comprises a heavy chain variable region sequence set forth in SEQ ID NO: 3 and a light chain variable region sequence set forth in SEQ ID NO: 39, and wherein the antibody comprises a human IgG1 Fc region with LALA and/or YTE mutations.

2. An isolated antibody that binds IL-13, wherein the antibody comprises a heavy chain variable region sequence set forth in SEQ ID NO: 3 and a light chain variable region sequence set forth in SEQ ID NO: 39.

3. An isolated antibody that binds IL-13, wherein the antibody comprises a heavy chain variable region sequence set forth in SEQ ID NO: 3, a light chain variable region sequence set forth in SEQ ID NO: 39, a constant heavy chain sequence set forth in SEQ ID NO: 439, and a constant light chain sequence set forth in SEQ ID NO: 469.

4. The isolated antibody of claim 1, wherein the antibody is a humanized or chimeric antibody.

5. The isolated antibody of claim 4, wherein the antibody is a humanized antibody.

6. The isolated antibody of claim 2, wherein the antibody comprises a human IgG1 Fc region.

7. The isolated antibody of claim 1, wherein the antibody is a monoclonal antibody.

8. The isolated antibody of claim 1, wherein the antibody binds an IL-13 sequence set forth in SEQ ID NO: 472 or SEQ ID NO: 473.

9. The isolated antibody of claim 1, wherein the antibody binds to an IL-13 sequence set forth in SEQ ID NO: 472 or SEQ ID NO: 473 with a K_D of less than or equal to about 1, 2, 3, 4, 5, 6, 7, 8, 9 x 10^{-9} M, as measured by surface plasmon resonance (SPR).

10. The isolated antibody of claim 1, wherein the antibody binds to an IL-13 sequence set forth in SEQ ID NO: 472 or SEQ ID NO: 473 with a K_D of less than or equal to about 1 x 10^{-10} M, as measured by SPR.

11. The isolated antibody of claim 1, wherein the antibody binds to human IL-13 with a K_D of less than or equal to about 1 x 10^{-9} M, as measured by SPR.

12. The isolated antibody of claim 1, wherein the antibody comprises a human IgG1 Fc region with LALA and YTE mutations.

13. The isolated antibody of claim 1, wherein the antibody comprises a human IgG1 Fc region with YTE mutations.

14. The isolated antibody of claim 1, wherein the antibody comprises a human IgG1 Fc region with LALA mutations.

15. The isolated antibody of claim 2, wherein the antibody binds to an IL-13 sequence set forth in SEQ ID NO: 472 or SEQ ID NO: 473 with a K_D of less than or equal to about 1 x 10^{-10} M, as measured by SPR.

16. The isolated antibody of claim 15, wherein the antibody comprises a human IgG1 Fc region with LALA and YTE mutations.

17. The isolated antibody of any one of the preceding claims, wherein the antibody is formulated for subcutaneous injection.

18. The isolated antibody of any one of claims 1-16, wherein the antibody is formulated for intravenous injection.

19. A composition comprising the isolated antibody of any one of the preceding claims and a pharmaceutically acceptable excipient.

20. A kit comprising:

(a) the isolated antibody that binds IL-13 of any one of claims 1-18; and

(b) instructions for use.

21. The isolated antibody of any one of claims 1-18 for use in treating an inflammatory disorder or disease in a mammalian subject in need thereof.

22. The isolated antibody for use of claim 21, wherein the inflammatory disorder or disease is atopic dermatitis.

23. The isolated antibody for use of claim 22, wherein the treatment reduces disease severity in a subject and wherein disease severity is assessed by an Atopic Dermatitis Disease Severity Outcome Measure.

24. The isolated antibody for use of claim 21, wherein the inflammatory disorder or disease is selected from the group consisting of asthma, idiopathic pulmonary fibrosis, alopecia areata, chronic sinusitis with nasal polyps, Chronic Rhinosinusitis without Nasal Polyps (CRSsNP), eosinophilic esophagitis (EoE), Eosinophilic gastrointestinal disorder or disease (ENID), Churg-Strauss syndrome/Eosinophilic granulomatosis with polyangiitis (EGPA), Prurigo Nodularis (PN), Chronic Spontaneous Urticaria (CSU), Chronic Pruritis of Unknown Origin (CPUO), Bullous Pemphigoid (BP), Cold Inducible Urticaria (ColdU), Allergic Fungal Rhinosinusitis (AFRS), Allergic Bronchopulmonary Aspergillosis (ABPA), and Chronic Obstructive Pulmonary Disease (COPD).

25. The isolated antibody for use of claim 24, wherein the ENID is selected from the group consisting of Eosinophilic Gastritis (EoG), Eosinophilic Enteritis (EoN), Eosinophilic Colitis (EoC), and Eosinophilic Gastroenteritis (EGE).

26. An isolated polynucleotide or set of polynucleotides encoding the isolated antibody of any of claims 1-18.

27. A vector or set of vectors comprising the polynucleotide or set of polynucleotides of claim 26.

28. A host cell comprising the polynucleotide or set of polynucleotides of claim 26 or the vector or set of vectors of claim 27.

29. The host cell of claim 28, wherein the host cell is a Chinese hamster ovary (CHO) cell.

30. A method of producing an antibody, the method comprising expressing the antibody with the host cell of claim 28 or 29 and isolating the expressed antibody.